References

Unresolved reference

2023 · External reference

Therapeutic neovascularization for coronary disease: current state and future prospects.

10.1007/s00395-011-0200-1 · 2011 · External reference

ESC Guidelines for the diagnosis and management of chronic coronary syndromes

10.1093/eurheartj/ehz425 · 2019 · External reference

Mechanism of Action of DPP-4 Inhibitors—New Insights

10.1210/jc.2012-2396 · 2012 · External reference

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

10.1056/nejmoa1501352 · 2015 · External reference

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes.

10.1001/jama.2019.13772 · 2019 · External reference

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

10.1001/jama.2018.18269 · 2019 · External reference

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

10.1016/s0140-6736(19)31149-3 · 2019 · External reference

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

10.1186/s12933-017-0593-8 · 2017 · External reference

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

10.1056/nejmoa1305889 · 2013 · External reference

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials.

10.4330/wjc.v13.i10.585 · 2021 · External reference

Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes.

10.1016/j.jacasi.2022.09.015 · 2023 · External reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

10.1056/nejmoa1307684 · 2013 · External reference

Sitagliptin protects diabetic rats with acute myocardial infarction through induction of angiogenesis: role of IGF-1 and VEGF

10.1139/cjpp-2018-0670 · 2019 · External reference

Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemia-reperfusion injury in rats with diabetes mellitus type 2.

10.1111/1440-1681.13450 · 2021 · External reference

Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model.

10.3390/ijms19103226 · 2018 · External reference

Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1–7) Balance in Experimental Chronic Kidney Disease.

10.3390/ijms20081940 · 2019 · External reference

Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction

10.1111/bph.13686 · 2017 · External reference

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

10.1093/eurjhf/hfr146 · 2012 · External reference

Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study.

10.14814/phy2.15744 · 2023 · External reference

DPP-4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia.

10.14814/phy2.15976 · 2024 · External reference

Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia.

10.1161/jaha.122.028623 · 2023 · External reference

Intramyocardial Injection of Hypoxia‐conditioned Extracellular Vesicles Modulates Apoptotic Signaling in Chronically Ischemic Myocardium.

2023 · External reference

QuPath: Open source software for digital pathology image analysis.

10.1038/s41598-017-17204-5 · 2017 · External reference

The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms.

10.3390/biom13010119 · 2023 · External reference

New insights into TGF-β/Smad signaling in tissue fibrosis

10.1016/j.cbi.2018.07.008 · 2018 · External reference

Unresolved reference

2012 · External reference

The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.

10.3390/ijms19030778 · 2018 · External reference

The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis.

2020 · External reference

The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis.

10.1038/s41467-018-07858-8 · 2019 · External reference

Delayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3).

10.1152/ajplung.00455.2017 · 2019 · External reference

Alpha-Smooth Muscle Actin Expression Upregulates Fibroblast Contractile Activity

10.1091/mbc.12.9.2730 · 2001 · External reference

Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects

10.1056/nejmoa054862 · 2006 · External reference

Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake.

2018 · External reference

SIRT1 and insulin resistance.

10.1038/nrendo.2009.101 · 2009 · External reference

Protein Kinase C Function in Muscle, Liver, and β-Cells and Its Therapeutic Implications for Type 2 Diabetes.

10.2337/db07-1769 · 2008 · External reference

Protein kinase C Theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101).

10.1074/jbc.c400186200 · 2004 · External reference

STAT5 Activation and Cardioprotection by Remote Ischemic Preconditioning in Humans

10.1161/circresaha.111.259556 · 2012 · External reference

An Update on the Multifaceted Roles of STAT3 in the Heart.

10.3389/fcvm.2019.00150 · 2019 · External reference

The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.

10.3389/fphys.2017.00777 · 2017 · External reference